The hypocrisy of Express Scripts

  • Express Scripts said “despite promises to limit price increases, drugmakers are trying to game the market by delaying generic competition, blocking access to safe and effective biosimilars, and coyly deferring – not cancelling – list-price increases. This is why our work to expand access and maximize value is more important now than ever”.
  • In 2015, Express Scripts, the largest PBM-only company in the U.S., reported a profit of more than $660 million, from sales exceeding $25 billion.
  • In 2017, pharmacy benefits giant Express Scripts saw its net income skyrocket by 33% year-over-year to $4.51 billion.

Continue reading